Abstract

ABSTRACTThe 2015–2016 Zika virus (ZIKV) epidemic in the Americas and the Caribbean demonstrated that clinical assays to detect, distinguish, and characterize immune responses to flaviviral infections are needed. ZIKV and dengue virus (DENV) are mosquito-transmitted flaviviruses sharing overlapping geographic distributions and have significant sequence similarities that can increase the potential for antibody and T cell cross-reaction. Using nonstructural protein 1-based enzyme-linked immunosorbent assays (ELISAs), we determined the serostatus of individuals living in a region of DENV and ZIKV endemicity in Brazil, identifying individuals with primary DENV (pDENV) and primary ZIKV (pZIKV), ZIKV with primary DENV (ZIKVwpDENV), and secondary DENV (sDENV) infections; the presence of pDENV and pZIKV was further confirmed by neutralization tests. Development of an enzyme-linked immunosorbent spot (ELISPOT) assay for DENV and ZIKV structural and nonstructural (NS) protein antigens enabled us to distinguish infections by these viruses based on T cell responses and to characterize those responses. We found that gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α) T cell responses to NS3 differentiated DENV and ZIKV infections with 94% sensitivity and 92% specificity. In general, we also showed that pDENV and sDENV cases and pZIKV and ZIKVwpDENV cases elicit similar T cell response patterns and that HIV-infected individuals show T cell responses that are lower than those shown by HIV-negative individuals. These results have important implications for DENV and ZIKV diagnostic and vaccine development and provide critical insights into the T cell response in individuals with multiple flaviviral infections.

Highlights

  • The 2015–2016 Zika virus (ZIKV) epidemic in the Americas and the Caribbean demonstrated that clinical assays to detect, distinguish, and characterize immune responses to flaviviral infections are needed

  • We previously showed that combinations of dengue virus (DENV) and ZIKV nonstructural protein 1 (NS1)-based enzyme-linked immunosorbent assays (ELISAs) were capable of distinguishing confirmed cases with respect to past and present flaviviral infections, including primary DENV and primary ZIKV, ZIKV with primary DENV (ZIKVwpDENV), and secondary DENV infections [12]

  • We report on the characterization of late-convalescent-phase antibody and T cell responses in individuals from Salvador, Brazil, a region of DENV hyperendemicity that was burdened by the 2015–2016 ZIKV outbreak

Read more

Summary

Introduction

The 2015–2016 Zika virus (ZIKV) epidemic in the Americas and the Caribbean demonstrated that clinical assays to detect, distinguish, and characterize immune responses to flaviviral infections are needed. The emergence of ZIKV in regions of DENV endemicity is of particular concern and relevant for diagnostic and vaccine development The cocirculation of these genetically similar viruses can result in coinfection or sequential exposure, which has been shown to potentiate cross-reactive immunity at both the antibody (Ab) and T cell levels [9,10,11,12]. We previously showed that combinations of DENV and ZIKV NS1-based enzyme-linked immunosorbent assays (ELISAs) were capable of distinguishing confirmed cases with respect to past and present flaviviral infections, including primary DENV (pDENV) and primary ZIKV (pZIKV), ZIKV with primary DENV (ZIKVwpDENV), and secondary DENV (sDENV) infections [12] These ELISAs are applicable for routine serological tests for DENV and ZIKV and are useful in retrospective studies to identify individuals with primary and multiple flaviviral infections. We previously developed a modified anthrax toxin (N-terminal domain of lethal factor [LFn])-based enzyme-linked immunosorbent spot (ELISPOT) assay, which revealed longterm T cell responses that were ZIKV and DENV specific with respect to NS3 protease but cross-reactive with respect to NS3 helicase in individuals infected with DENV and

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call